These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
841 related articles for article (PubMed ID: 28025814)
1. Phenomenology, Structure, and Dynamic of Psychedelic States. Preller KH; Vollenweider FX Curr Top Behav Neurosci; 2018; 36():221-256. PubMed ID: 28025814 [TBL] [Abstract][Full Text] [Related]
2. Dreams and Psychedelics: Neurophenomenological Comparison and Therapeutic Implications. Kraehenmann R Curr Neuropharmacol; 2017; 15(7):1032-1042. PubMed ID: 28625125 [TBL] [Abstract][Full Text] [Related]
3. The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Dittrich A Pharmacopsychiatry; 1998 Jul; 31 Suppl 2():80-4. PubMed ID: 9754838 [TBL] [Abstract][Full Text] [Related]
4. Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics. Hovmand OR; Poulsen ED; Arnfred S J Psychopharmacol; 2024 Jan; 38(1):19-32. PubMed ID: 37969069 [TBL] [Abstract][Full Text] [Related]
5. Increased Global Functional Connectivity Correlates with LSD-Induced Ego Dissolution. Tagliazucchi E; Roseman L; Kaelen M; Orban C; Muthukumaraswamy SD; Murphy K; Laufs H; Leech R; McGonigle J; Crossley N; Bullmore E; Williams T; Bolstridge M; Feilding A; Nutt DJ; Carhart-Harris R Curr Biol; 2016 Apr; 26(8):1043-50. PubMed ID: 27085214 [TBL] [Abstract][Full Text] [Related]
6. Serotonergic psychedelics LSD & psilocybin increase the fractal dimension of cortical brain activity in spatial and temporal domains. Varley TF; Carhart-Harris R; Roseman L; Menon DK; Stamatakis EA Neuroimage; 2020 Oct; 220():117049. PubMed ID: 32619708 [TBL] [Abstract][Full Text] [Related]
7. Psychedelic medicine: The biology underlying the persisting psychedelic effects. Kuypers KPC Med Hypotheses; 2019 Apr; 125():21-24. PubMed ID: 30902145 [TBL] [Abstract][Full Text] [Related]
17. Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience. Pokorny T; Preller KH; Kraehenmann R; Vollenweider FX Eur Neuropsychopharmacol; 2016 Apr; 26(4):756-66. PubMed ID: 26875114 [TBL] [Abstract][Full Text] [Related]
18. An introduction to psychedelic neuroscience. Calvey T; Howells FM Prog Brain Res; 2018; 242():1-23. PubMed ID: 30471677 [TBL] [Abstract][Full Text] [Related]
19. LSD, madness and healing: Mystical experiences as possible link between psychosis model and therapy model. Wießner I; Falchi M; Palhano-Fontes F; Feilding A; Ribeiro S; Tófoli LF Psychol Med; 2023 Mar; 53(4):1151-1165. PubMed ID: 34253268 [TBL] [Abstract][Full Text] [Related]
20. Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions. Garcia-Romeu A; Richards WA Int Rev Psychiatry; 2018 Aug; 30(4):291-316. PubMed ID: 30422079 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]